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Human lupus is strongly associated with a gene expression signature characterized
by over-expression of Type I interferon-regulated genes. A strong interferon signature
generally is not seen in the standard mouse models of lupus, despite considerable
evidence for the involvement of toll-like receptor-driven interferon production. In contrast,
pristane-induced lupus exhibits a prominent TLR7-dependent interferon signature. Impor-
tantly, genetic disorders with dysregulated interferon production in both human beings
and mice cause severe autoinflammatory diseases but not the typical manifestations of
lupus, suggesting that interferon over-production is insufficient to cause systemic lupus
erythematosus itself. Single-gene models in mice suggest that lupus-like disease may
result from abnormalities in B-cell activation and the clearance of dead cells. Pristane
may mimic human systemic lupus erythematosus by causing synergistic abnormalities
in interferon production along with defective clearance of apoptotic cells and over-active
B-cell signaling.
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B-cell activation
Systemic lupus erythematosus (SLE) is defined by a complex clinical syndrome (e.g., arthritis, skin
rashes, oral ulcers, serositis, glomerulonephritis, nervous system involvement) and the production
of antinuclear antibodies (ANAs) such as anti-Sm and anti-double-stranded (ds) DNA (1, 2). It has
become increasingly clear that over-production of Type I interferon (IFN-I) is strongly associated
with SLE and that this cytokine is involved in disease pathogenesis. Over-expression of a group
of interferon-stimulated genes (ISGs) by peripheral blood mononuclear cells from SLE patients
is termed the interferon signature (3, 4). This gene expression program is seen in over two-
thirds of adult and nearly all pediatric SLE patients who are defined by four or more of the ACR
Classification Criteria (2). Adults exhibiting the interferon signature have an increased frequency
of autoantibodies against dsDNA, Sm, RNP, and Ro, lower complement levels, and a higher fre-
quency of lupus nephritis and possibly cutaneous manifestations than interferon signature negative
patients (5–7).
Polymorphisms of a number of genes have been identified by genome-wide association studies
(GWAS) to be linked to disease susceptibility in human beings, and some, such as IRF-5, are linked
to the regulation of IFN-I production (8, 9). Additionally, therapeutic use of IFNα and trisomy
of the Type I IFN gene cluster are associated with lupus-like autoimmunity in human beings (10,
11). However, despite the strong association of IFN-I over-production with SLE and evidence
that the severity of lupus-like disease usually is attenuated in mice lacking the Type I interferon
receptor (IFNAR) (12, 13), our understanding of the relationship of IFN-I to SLE pathogenesis
is incomplete. Animal models may help address several questions, including: (1) Why do only a
few patients (one of 987 in one study) treated with IFNα develop lupus (14)? (2) Why does IFNα
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induce lupus-like manifestations, whereas IFNβ generally does
not (10)? (3) Why does treatment with neutralizing antibodies
against IFNα (e.g., rontalizumab) lead to improvement of lupus in
the interferon signature negative subset but not in the interferon
signature high subset (15)? (4) Why do children with “interfer-
onopathies,” who are identified by the presence of a strong inter-
feron signature, develop vasculopathy, nervous system disease,
and other inflammatory manifestations but only rarely lupus (16,
17)? (5)Why do Stimulator of IFNGenes (STING)-deficient lupus
mice paradoxically develop more severe lupus-like disease than
controls, despite the fact that human gain-of-function mutations
are associated with inflammatory disease and a high interferon
signature (18, 19)? (6)Whydoes IFN-I protectMRL/lprmice from
lupus, while exacerbating it in other strains (20)? (7) How is IFN-I
linked to the production of lupus-specific autoantibodies?
Interferon in Spontaneous Lupus Models
Several mouse strains develop spontaneous lupus-like disease,
but they usually do not develop sufficient clinical/serological
manifestations to meet the criteria used to classify human SLE
(2) (Table 1). The most-studied strains are (NZBNZW)F1
(NZB/W), NZM2410 and related strains (inbred derivatives of
NZB/W selected for nephritis), MRL/lpr, and BXSB male mice,
although this is not a complete list. Other strains, some with
single-gene defects, develop more limited lupus-like disease (see
below). It is probably not appropriate to equate the production
of ANAs or anti-dsDNA autoantibodies, even in the presence
of glomerular immune deposits (IgG/IgM or C3 staining), with
what would be defined as “SLE” in human beings by standard
clinical criteria (2). Nevertheless, partial lupus-like syndromes in
mice may provide important insights into the pathogenesis of
the individual manifestations of SLE and the spontaneous models
have the advantage that as in human SLE, genetic susceptibility
factors are important. However, since the candidate susceptibility
loci identified in mice often do not appear to be major factors in
human SLE, it is necessary to carefully relate these models to clin-
ical subsets of human SLE. This review focuses on the suitability
of mouse models for studying the interferon signature positive
subset of SLE, which as noted above is characterized clinically
by the production of specific autoantibodies with an increased
prevalence of nephritis and possibly cutaneous manifestations.
NZB/W and NZM
NZB/W and NZM (NZM2410, NZM2328, others) mice are
similar, developing severe glomerulonephritis and anti-dsDNA
autoantibodies without other clinical or serological manifes-
tations of lupus (21) (Table 1). Anti-Sm/RNP autoantibodies
are absent. We have found that they exhibit a weak interferon
signature at 6months and but not at 2months of age (Szeto,
et al., manuscript in preparation). As in human beings, NZB/W
lupus is exacerbated by IFN-I over-expression with accelerated
anti-dsDNA autoantibody production, increased proteinuria, and
worse glomerulonephritis (22). NZBmice develop severe IFNAR-
dependent autoimmune hemolytic anemia but otherwise have
only mild lupus-like manifestations (12). It is not known whether
or not they exhibit an interferon signature.
MRL+/+ and MRL/lpr
MRL+/+ develop late-onset, mild, lupus-like disease, manifested
primarily by autoantibody production (Table 1). Deficiency of
Fas (lpr mutation) greatly accelerates the onset of anti-Sm and
anti-dsDNA/chromatin autoantibodies, as well as severe glomeru-
lonephritis in MRL/lpr mice. MRL/lpr mice do not develop anti-
RNP autoantibodies, although they are strongly anti-Sm posi-
tive. In contrast to NZB/W, MRL+/+ and MRL/lpr mice do not
show evidence of IFN-I over-production at 2 or 6months of age
(Szeto, et al., manuscript in preparation). In sharp contrast to the
IFN-dependent disease in NZB/W, IFNAR deficiency exacerbates
autoantibodies and nephritis inMRL/lprmice (20). Paradoxically,
although lupus-like disease is very mild in B6/lpr mice, autoanti-
body production is attenuated by IFNAR deficiency (23). Thus,
background genes unique to MRL vs. B6 may play a major role
in determining the phenotype of lupus-like disease and its IFN-I
dependence.
BXSB Male
Although human and most spontaneous murine lupus is more
common and frequently more severe in females, development
of lupus in BXSB mice is limited to males (Table 1). This is
due to the presence of two active copies of TLR7 (one on the
X-chromosome and another on theY-chromosome) (24, 25).Male
BXSB mice develop anti-dsDNA and RNA autoantibodies with
nephritis. Female mice with only one active copy of TLR7 are
protected. Increasing the copy number of TLR7 in B6 mice also
TABLE 1 | Selected animal models of SLE.
Animal modela IFN signature Anti-DNA Anti-Sm/RNP Clinicalb SLE criteriac
NZB/W, NZM2410 Weak Yes No ANAs, severe LN 3
MRL/lpr Absent Yes Yes ANAs, severe LN, arthritis, skin rash? 6
MRL+/+ Absent Low (late) Yes (late) ANAs 2
B6/lpr Absent No No ANAs 1
BXSB male N/A Yes No ANAs, severe LN 3
BAFF Tg N/A Yes No ANAs, LN 3
MerTK KO N/A Yes No ANAs, LN, arthritis 4
Pristane Strong Yes Yes ANAs, LN, arthritis, DAH, anemia, serositis 8
aTg, transgenic; KO, knockout; N/A, not available.
bANAs, antinuclear antibodies; LN, lupus nephritis; DAH, diffuse alveolar hemorrhage.
cNumber of the SLICC criteria for classification of SLE that are met (in human beings, four criteria are needed to define lupus with 95% certainty, at least one clinical and one laboratory
criteria).
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increases the production of anti-RNA autoantibodies (26). BXSB
male mice produce high levels of anti-dsDNA antibodies and
anti-RNA antibodies, but not anti-Sm/RNP. They also develop
severe nephritis. It is not knownwhether they exhibit an interferon
signature.
Role of Endogenous TLR7 and TLR9
Ligands in IFN-I Production
The endosomal toll-like receptors (TLRs) TLR7 and TLR9 pro-
mote IFN-I production via a signaling pathway involving the
adapter proteinMyD88, kinases (IRAK1, IRAK4, TRAF6, TRAF3,
and TAK1), and the transcription factor IRF7 (27). Although
there is some flexibility in the optimal stimulatory sequences,
TLR7/TLR8 and TLR9 are receptors for AU-rich single-stranded
RNA and non-methylated cytosine-guanosine (CpG) motifs in
DNA, respectively (28). Although they evolved as pattern recog-
nition receptors for microbial nucleic acids, they can recognize
endogenous nucleic acids, includingU1RNA (RNAcomponent of
U1 small ribonucleoproteins, recognized by anti-Sm/RNP autoan-
tibodies) and certain endogenous DNA motifs (28). TLR7 and
TLR9 are expressed in dendritic cell (DC) subsets (high levels
in plasmacytoid dendritic cells, pDCs), macrophages, and B-cells
(29, 30). In pDCs and macrophages, TLR7/TLR9 engagement
strongly promotes IFN-I production. Conversely, TLR7 expres-
sion is strongly stimulated by IFN-I. In human beings as well as
mice, TLR8 is not associated with immunopathology, possibly
reflecting the fact that pDCs and B-cells do not express it (28).
Endosomal TLRs play a central role in autoimmunity in spon-
taneous lupus models. Although IFN-I production is not directly
involved in the pathogenesis of lupus-like disease in MRL/lpr
mice, anti-Sm autoantibodies are abolished in TLR7-deficient
mice, whereas anti-dsDNA is TLR9-dependent (28, 31). Treat-
ment with a dual TLR7/TLR9 inhibitor prevents disease progres-
sion in NZB/W mice, and there is genetic evidence that TLR7 is
involved in human SLE (32, 33). The dependence of lupus-like
disease in MRL/lpr mice on TLR7/TLR9, but not IFN-I, suggests
that TLR signalingmay have a role beyond the induction of IFN-I.
Consistent with that possibility, TLR7/TLR9 signaling has B-cell-
intrinsic effects on B-cell proliferation, terminal differentiation of
memory B-cells, and spontaneous germinal center formation (34).
It has become increasingly clear that the TLR7/TLR9 ligands
driving IFN-I production in SLE are derived from endogenous
nucleic acids. There are numerous examples of lupus-like autoim-
munity in mice with defective clearance of dead cells (35), though
less evidence is available that the disease is IFN-I-dependent. Cells
undergoing apoptosis expose phosphatidylserine (PtdSer) on the
outer leaflet of the cell membrane (36). This is recognized by a
variety of receptors mediating the rapid phagocytosis and degra-
dation of dead cells before they can release endogenous nucleic
acids capable of engaging TLR7/TLR9. PtdSer on apoptotic cells is
bound by MFG-E8 (a secreted protein), serum proteins (protein
S and Gas6), and complement component C1q. Phagocytosis of
apoptotic cells coated by MFG-E8 is facilitated by the integrins
αvβ3 and αvβ5, whereas uptake of cells coated with protein S
or Gas6 is mediated by the “TAM receptors” Tyro3, Axl, and
Mertk (35), and uptake of C1q-opsonized cells is mediated by
the scavenger receptor SCARF1 (37). This promotes the non-
inflammatory clearance of dead cells and the suppression of
TLR signaling. Deficiency of Mertk or other TAM receptors in
mice causes lupus-like disease manifestations, such as nephritis,
arthritis, and production of anti-dsDNA autoantibodies, but not
anti-Sm/RNP (38) (Table 1). The phenotype is most severe in
TAM triple knockout mice, but apparent in single and double
knockout animals (39). C1q-deficient mice exhibit autoantibod-
ies, glomerular accumulation of dead cells, and nephritis (40).
Similarly, the risk of lupus in C1q-deficient human beings is
93%. There is considerable redundancy of the receptors utilized
for clearing apoptotic cells. Although single-gene mutations fre-
quently are associated with lupus-like phenomena, that is not
always the case. For example, deficiency of the PtdSer receptor
Tim-4 is not associated with lupus-like disease (41).
Interferon in Human and Murine
Single-Gene Lupus Models
Mice with deletion or over-expression of certain single genes
develop limited lupus-like syndromes mediated in part by IFN-I
production. These disorders are associated with a limited spec-
trum of autoantibodies, usually only anti-DNA/chromatin, and
renal immune complex deposition with or without histological
changes and proteinuria (Table 1).
BAFF-Transgenic Mice
B-cell survival and maturation are enhanced by transgenic (Tg)
expression of B-cell activating factor of the TNF family (BAFF,
also known as BLyS), which activates NF-κB2 in B-cells (42).
BAFF over-expression is seen in SLE patients as well as NZB/W
and MRL/lpr mice (43). Moreover, BAFF inhibitors (TACI-Ig
in mice, belimumab in human beings) reduce disease severity.
Increased BAFF-TACI signaling decreases the stringency of neg-
ative selection of autoreactive B-cells in the periphery, promot-
ing survival of autoreactive B-cells (44). BAFF-Tg mice produce
high levels of anti-dsDNA and histone autoantibodies as well
as rheumatoid factor, but not anti-Sm/RNP (45). Autoantibody
production in thesemice is T-cell independent but requires B-cell-
intrinsic signals through the TLR/MyD88 pathway (45). TLR7/9
signaling strongly up-regulates expression of TACI, one of the
receptors for BAFF and IFN-I stimulates BAFF expression by
macrophages and dendritic cells (45). However, it is unclear
whether BAFF-Tg mice exhibit the interferon signature.
Other single-gene defects affecting B-cell activa-
tion/maturation cause lupus-like disease. For example, deletion
of the tyrosine kinase Lyn or over-expression of Bruton’s tyrosine
kinase (Btk) is associated with lupus-like disease (46, 47). But
these disorders have not been linked to dysregulated IFN-I
production, suggesting that abnormalities in B-cell signaling may
promote autoimmunity by IFN-I-independent mechanisms.
“Interferonopathies” (TREM173, TREX1, MDA5,
DNaseII, and Other Defects)
In addition to the endosomal nucleic acid sensors
TLR3/TLR7/TLR8/TLR9, the cytoplasm contains sensors
for DNA and RNA, the primary function of which is to
detect microbial infection (48). These molecules also recognize
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endogenous nucleic acids, but in the normal state, self-DNA/RNA
is sequestered away from the sensors and degraded before it can
stimulate an IFN-I response (35, 49). However, when endogenous
nucleic acid is inefficiently degraded, it can engage the sensors,
resulting in interferon-mediated autoinflammatory diseases
(16). In pediatric populations, screening for these disorders is
carried out by testing for the interferon signature (17). Defects
in genes involved in the STING pathway are an example.
STING is an endoplasmic reticulum-associated protein that
recognizes cytoplasmic DNA, resulting in IFN-I production
via the activation of TBK1 and transcription factor IRF3 (19).
Human gain of function mutations in TREM173 (encodes
STING) causes an IFN-I-mediated autoinflammatory syndrome
characterized by cutaneous vasculopathy and pulmonary
inflammation (19). However, ANAs are not prominent and
lupus-like disease develops only rarely. Similarly, human
loss-of-function mutations in TREX1, a negative regulator of
STING (50), cause autoinflammatory disease manifested by
severe neurological impairment (encephalopathy, calcification
of the basal ganglia) caused by IFN-I production in the
central nervous system (Aicardi–Goutieres syndrome) (51).
They also are associated with familial chilblain lupus, an
erythematous/violaceous rash typically involving the hands
and/or feet but distinct from the classic SLE rashes. ANAs
sometimes are produced, but not anti-dsDNA or anti-Sm/RNP,
and typical clinical manifestations of SLE are rare. Murine Trex1
deficiency is lethal, causing autoinflammatory disease with
myocarditis and autoantibodies against cardiac muscle, but not
the typical lupus autoantibodies. Interestingly, gain-of-function
mutations of the cytoplasmic RNA sensor MDA5 cause an
IFN-I-mediated autoinflammatory syndrome similar to disorders
of the STING/TREX1 axis (52). STING paradoxically suppresses
lupus-like disease inMRL/lprmice and in pristane-induced lupus.
STING-deficient mice develop accelerated glomerulonephritis
and mortality and STING-deficient MRL/lpr mice develop an
interferon signature (18). The exacerbation of lupus may be
related to low expression of A20, SOCS1, and SOCS3, which
are negative regulators of TLR signaling, in STING-deficient
mice.
Abnormal endosomal degradation of DNA released by apop-
totic cells by DNase II also causes an inflammatory disorder (35).
DNase II deficiency is embryonic lethal, but conditional knockout
mutants develop IFN-I-mediated arthritis resembling rheumatoid
arthritis with low levels of anti-dsDNA autoantibodies (10% of the
level seen inMRL/lprmice) (35). Although TLR independent, the
disease is STING dependent (53).
The phenotypes of these interferonopathies illustrate an impor-
tant point that while over-production of IFN-I (as indicated by the
high interferon signature in such patients) is sufficient to cause
autoinflammatory disease, it is not sufficient to cause lupus, possi-
bly reflecting the synergistic effects of IFN-I over-production with
delayed phagocytosis of apoptotic cells and abnormal B-cell acti-
vation/maturation. That possibility is supported by the phenotype
of lupus-like disease in mice treated with pristane and by the fact
that exogenous IFNα administration (via an adenoviral vector)
is insufficient to induce lupus-like disease in non-autoimmune
prone mice (22).
Pristane-Induced Lupus
Pristane (2,6,10,14-tetramethylpentadecane) is an isoprenoid
alkane found in plants, shark liver, and mineral oil, a byprod-
uct of petroleum distillation. Intraperitoneal injection of pris-
tane in non-autoimmune prone mice, such as B6 or BALB/c,
causes a lupus-like syndrome with high levels of IgG anti-dsDNA,
anti-Sm/RNP, anti-Su, anti-ribosomal P, and other lupus-related
autoantibodies starting ~3months after treatment (54). As in
SLE patients, disease is more severe in females (55). The clini-
cal manifestations exhibit strain-to-strain variability, and include
immune complex-mediated glomerulonephritis (prominent in
BALB/c and SJL mice), arthritis (BALB/c), anemia (most strains),
and diffuse alveolar hemorrhage (DAH, B6, and B10 mice) (54,
56) (Table 1). Many of these manifestations are cytokine driven.
Like SLE patients, pristane-treated mice exhibit a strong IFN
signature and mice deficient in the IFNAR do not develop
autoantibodies or glomerulonephritis (54). In contrast, anemia
in pristane-treated mice is dependent on TNFα and independent
of IFN-I. The bone marrow of pristane-treated mice shows high
levels of TNFα and a remarkable accumulation of apoptotic cells,
abnormalities that are also present in the bone marrow of SLE
patients (57). The arthritis in pristane-treated mice also is likely
to be TNFα mediated as it is ameliorated by TNF inhibitor ther-
apy (58). IFN-I and TNFα production is TLR7 dependent (57,
59). Nephritis and anemia are abolished in TLR7-deficient mice,
but not in TLR9-deficient mice. Interestingly, the production of
autoantibodies against RNA-protein antigens is TLR7 dependent,
but so is production of anti-dsDNA autoantibodies. Pristane treat-
ment causes the accumulation of dead cells in the bone marrow
and other sites (57), which are likely to be the source of endoge-
nous TLR7 ligands driving the disease. Pristane induces lupus
in germ-free mice, emphasizing the probable role of endogenous
rather than microbial TLR7 ligands in disease pathogenesis (60).
IFN-I Production in Pristane-Induced Lupus
Although pristane-treated mice exhibit a robust IFN signature
and autoantibody production and nephritis are abolished in
IFNAR-deficient mice, the role of IFN-I in disease pathogenesis is
incompletely understood. A population of inflammatory (Ly6Chi)
monocytes produces most of the IFN-I in pristane-treated mice
(61), although smaller amounts are produced by pDCs. Para-
doxically, although wild-type B6 mice develop both autoantibod-
ies and an interferon signature, Fas-deficient (B6/lpr) mice are
refractory to the induction of autoantibodies by pristane despite
exhibiting an interferon signature (62). The explanation is under
investigation.
Conclusion
Animal models have led to a clearer understanding of the role of
IFN-I in the pathogenesis of lupus-like disease. One major effect
of IFN-I over-production is enhanced TLR7 expression and TLR7
signaling, whichmaymaintain IFN-I production as well as having
intrinsic effects on B-cell activation and maturation. However,
as illustrated by the interferonopathies, over-production of IFN-
I, although pro-inflammatory, does not suffice to induce lupus-
like disease. The pristane-lupus model suggests that the lupus
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phenotype depends onmore than just IFN-I. TNFα influences the
pathogenesis of some of the clinical manifestations (e.g., anemia,
arthritis), whereas others are independent of both TNFα and IFN-
I (e.g., DAH). By activating multiple inflammatory pathways as
well as promoting the accumulation of apoptotic cells/endogenous
TLR7 ligands and B-cell activation, the inducible pristane-lupus
model may afford a window into the roles played by the multiple
pathways shaping the widely variable phenotypes of SLE in differ-
ent patients.
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